Jump to the top of the page

Investment Banking

The Quarterly Rx: Q2 2023 U.S. Biopharma Recap

Biopharma markets closed the first half of 2023 with renewed optimism and an encouraging outlook for the rest of the year. That comes as major market indices have trended upward—with biopharma emerging as the most heavily weighted sector in the Russell 2000—despite macro concerns following the regional banking crisis.

Public financing markets have warmed, but private companies continue to face challenging decisions amid a slow IPO market and selective private financing market. Simultaneously, SMID-cap M&A helped recycle capital in the sector.

William Blair’s Biopharma team shares perspectives in the Quarterly Rx: Q2 2023 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • Shaping the Future: Innovations and Trends in Obesity Treatment

    William Blair biotech analysts Matt Phipps and Andy Hsieh discuss Andy’s innovative scoring system for evaluating investigational agents in obesity treatment. This system, highlighted in Andy’s report “Shaping the Future: Innovations and Trends in Obesity Treatment,” considers both weight loss and gastrointestinal side effects to provide a more comprehensive clinical assessment. Tune in to hear their insights on the future of obesity therapies, upcoming industry catalysts, and more.

    Listen to the podcast
  • Waste Connections, Inc.: Initiation of Research Coverage

    William Blair initiated research coverage of Waste Connections, Inc. (WCN $196.51), a vertically integrated solid waste, recycling, and E&P waste provider.

    Read more
  • The Quarterly Rx: Q1 2025 U.S. Biopharma Recap

    On Groundhog Day 2025, Punxsutawney Phil saw his shadow and, as per tradition, predicted six more weeks of winter. That proved apropos of biopharma’s performance in the first quarter of 2025, as the sector finds itself reliving existential anxieties.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures